StockData
MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3065% below fair value
$1.17−0.01 (-0.85%)

Close on Nov 17, 2026Market cap $120.75MP/E –Yield –

MaxCyte net income

Net income is the profit left for shareholders after every expense, interest and tax.

MaxCyte's net income for the twelve months ending Jun 30, 2026 was -$35.64M. For fiscal 2025 it was -$44.63M. The highest annual figure on record is -$11.82M in fiscal 2020.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$44.63M–
FY2024Dec 31, 2024-$41.06M–
FY2023Dec 31, 2023-$37.92M–
FY2022Dec 31, 2022-$23.57M–
FY2021Dec 31, 2021-$19.08M–
FY2020Dec 31, 2020-$11.82M–
FY2019Dec 31, 2019-$12.90M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.87M–
Q1 FY2026Mar 31, 2026-$4.75M–
Q4 FY2025Dec 31, 2025-$9.60M–
Q3 FY2025Sep 30, 2025-$12.42M–
Q2 FY2025Jun 30, 2025-$12.36M–
Q1 FY2025Mar 31, 2025-$10.26M–
Q4 FY2024Dec 31, 2024-$10.60M–
Q3 FY2024Sep 30, 2024-$11.56M–
Q2 FY2024Jun 30, 2024-$9.38M–
Q1 FY2024Mar 31, 2024-$9.53M–
Q4 FY2023Dec 31, 2023-$5.28M–
Q3 FY2023Sep 30, 2023-$11.25M–
Q2 FY2023Jun 30, 2023-$10.51M–
Q1 FY2023Mar 31, 2023-$10.88M–
Q4 FY2022Dec 31, 2022-$4.81M–
Q3 FY2022Sep 30, 2022-$6.43M–
Q2 FY2022Jun 30, 2022-$8.26M–
Q1 FY2022Mar 31, 2022-$4.07M–
Q4 FY2021Dec 31, 2021-$4.87M–
Q3 FY2021Sep 30, 2021-$2.68M–
Q2 FY2021Jun 30, 2021-$4.42M–
Q1 FY2021Mar 31, 2021-$7.11M–
Q4 FY2020Dec 31, 2020-$2.65M–
Q3 FY2020Sep 30, 2020-$3.10M–
Q2 FY2020Jun 30, 2020-$3.00M–
Q1 FY2020Mar 31, 2020-$3.06M–

More MaxCyte figures

See a number that looks wrong?